Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them.
PURPOSE: Randomized phase II trial to determine the effectiveness of monoclonal antibody
therapy in treating patients who have advanced kidney cancer that cannot be surgically
removed.